lomitapide (Juxtapid)
Jump to navigation
Jump to search
Indications
- FDA-approved as an orphan drug (Dec 2012) to treat homozygous familial hypercholesterolemia
Mechanism of action
- inhibits the microsomal triglyceride transfer protein MTTP necessary for VLDL assembly & secretion in the liver
- reduces LDL cholesterol, total cholesterol, apolipoprotein B, & non-HDL cholesterol
More general terms
References
- ↑ Wikipedia: Lomitapide http://en.wikipedia.org/wiki/Lomitapide
- ↑ Raal FJ Lomitapide for homozygous familial hypercholesterolaemia. The Lancet, Volume 381, Issue 9860, Pages 7 - 8, 5 January 2013 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23122767 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61845-5/fulltext
- ↑ FDA Approves Aegerion Pharmaceuticals' JUXTAPID(TM) (lomitapide) Capsules for Homozygous Familial Hypercholesterolemia (HoFH) http://ir.aegerion.com/releasedetail.cfm?ReleaseID=728650